

Catherine M Sherwin,, Fcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2799080/publications.pdf>

Version: 2024-02-01

171
papers

3,453
citations

125106

35
h-index

252626

46
g-index

172
all docs

172
docs citations

172
times ranked

4455
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2024, 19, 111-121.	0.4	2
2	Effect of Curcumin on Oxidative Stress, Inflammatory Response and Kidney Biochemical Parameters Among Kidney Disease Patients: A Systematic Review. <i>Natural Products Journal</i> , 2023, 13, .	0.1	0
3	Evidence for Systemic Reactive Oxygen Species in UVB-mediated Microvesicle Formation. <i>Photochemistry and Photobiology</i> , 2022, 98, 242-247.	1.3	3
4	Effects and Mechanisms of Medicinal Plants on Healing Scars: A Systematic Review. <i>Current Traditional Medicine</i> , 2022, 8, .	0.1	1
5	Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. <i>Frontiers in Pharmacology</i> , 2022, 13, 883216.	1.6	5
6	Relationship between serum vitamin D and hip fracture in the elderly: a systematic review and meta-analysis. <i>Journal of Bone and Mineral Metabolism</i> , 2022, 40, 541-553.	1.3	10
7	Population pharmacokinetics of olanzapine in children. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 542-554.	1.1	7
8	Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 263-269.	2.3	9
9	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. <i>AAPS Journal</i> , 2021, 23, 53.	2.2	12
10	Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4560-4576.	1.1	23
11	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 747-765.	1.5	1
12	Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. <i>Paediatric Drugs</i> , 2021, 23, 499-513.	1.3	8
13	Maternal Exposure and Neonatal Effects of Drugs of Abuse. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S142-S155.	1.0	6
14	Effects of a new thyrotropic drug isolated from <i>Potentilla alba</i> on the male reproductive system of rats and offspring development. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 31.	1.2	2
15	Effects of Medicinal Plants on Human Hosts and Zoonotic Helminthic Infections: A Systematic Review. <i>Natural Products Journal</i> , 2021, 11, 472-490.	0.1	1
16	Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources?. <i>Frontiers in Pharmacology</i> , 2021, 12, 738504.	1.6	7
17	How can we improve the safe use of herbal medicine and other natural products? A clinical pharmacologist mission. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 935-944.	1.3	12
18	Spotlight Commentary: Why we need to pay attention to toxicity associated with herbal medicines. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1793-1794.	1.1	10

#	ARTICLE	IF	CITATIONS
19	The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease. <i>Frontiers in Pharmacology</i> , 2020, 11, 227.	1.6	3
20	Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review. <i>Paediatric Drugs</i> , 2020, 22, 279-293.	1.3	42
21	Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1920-1931.	0.6	4
22	Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E331-E339.	0.9	2
23	State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1-13.	1.6	50
24	Population Pharmacokinetic Modeling of Gentamicin in Pediatrics. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1584-1596.	1.0	11
25	A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. <i>Cell Transplantation</i> , 2019, 28, 1624-1631.	1.2	0
26	Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1191.	1.6	25
27	Generic drug products in paediatrics: Where are the data?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1871-1873.	1.1	5
28	Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. <i>Cancers</i> , 2019, 11, 1627.	1.7	59
29	Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. <i>Journal of Pharmacy Technology</i> , 2019, 35, 258-269.	0.5	1
30	Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. <i>International Immunopharmacology</i> , 2019, 76, 105868.	1.7	10
31	Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates. <i>AAPS Journal</i> , 2019, 21, 68.	2.2	3
32	Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 251-259.	1.6	19
33	Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 167, 7-14.	1.4	13
34	Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 44-52.	1.0	10
35	Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27629.	0.8	20
36	Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1462-1470.	2.3	27

#	ARTICLE	IF	CITATIONS
37	The effect of a prescription order requirement for pharmacist-administered vaccination on herpes zoster vaccination rates. <i>Vaccine</i> , 2019, 37, 631-636.	1.7	6
38	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Clinical Pharmacology</i> , 2019, 59, 198-205.	1.0	15
39	Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study. <i>Journal of Burn Care and Research</i> , 2019, 40, 91-96.	0.2	10
40	Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 59-66.	0.8	9
41	Use of Herbal Medicine by Pregnant Women: What Physicians Need to Know. <i>Frontiers in Pharmacology</i> , 2019, 10, 1483.	1.6	47
42	Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1628-1630.	1.1	2
43	Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1325-1336.	1.6	16
44	The clinical utility of pharmacometric models. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1413-1414.	1.1	3
45	Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1217-1228.	1.6	10
46	The Need for Pediatric Drug Development. <i>Journal of Pediatrics</i> , 2018, 192, 13-21.	0.9	53
47	Antibiotic Dosing in Pediatric Critically Ill Patients. , 2018, , 239-263.		3
48	Inclusion of pregnant and breastfeeding women in research – efforts and initiatives. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 215-222.	1.1	48
49	Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 80.	1.0	7
50	The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics. , 2018, , 203-222.		1
51	Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15
52	Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-12.	1.3	55
53	AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 77-84.	1.0	25
54	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 715-724.	1.5	15
56	Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 325-331.	0.8	32
57	Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. <i>Journal of Perinatology</i> , 2017, 37, 1093-1102.	0.9	14
58	The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1055-1069.	0.8	19
59	Riding (High) into the danger zone: a review of potential differences in chemical exposures in fighter pilots resulting from high altitude and G-forces. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 925-934.	1.5	8
60	Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1203-1214.	1.3	42
61	Use of TEG/Platelet Mapping to Dose-Adjust Platelet Inhibitors in Children Supported with the Berlin EXCOR: In Search of a Correlation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, S278-S279.	0.3	0
62	Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2709-2717.	1.1	3
63	Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. <i>BMJ Paediatrics Open</i> , 2017, 1, e000147.	0.6	11
64	Can <i>ad hoc</i> analyses of clinical trials help personalize treatment decisions?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2337-2338.	1.1	3
65	Hepatic Drug Metabolism in Pediatric Patients. , 2017, , 181-206.		8
66	Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. <i>International Journal of Adolescent Medicine and Health</i> , 2017, 29, .	0.6	0
67	Therapeutic Drug Monitoring in Pregnancy. , 2016, , 185-211.		1
68	Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 419-420.	1.0	2
69	Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial. <i>Congenital Heart Disease</i> , 2016, 11, 693-699.	0.0	9
70	Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 528-540.	1.0	8
71	Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children. <i>Pediatric Pulmonology</i> , 2016, 51, 1414-1421.	1.0	17
72	Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 590-596.	1.0	45

#	ARTICLE	IF	CITATIONS
73	Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1117-1127.	1.3	42
74	Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parentâ€™Metabolite Population Pharmacokinetic Model. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1395-1411.	1.6	37
75	Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 905-915.	1.3	48
76	Herbal medicines: challenges in the modern world. Part 4. Canada and United States. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1597-1609.	1.3	35
77	Newborns still lack drug data to guide therapy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1410-1411.	1.1	9
78	Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 33.	1.0	11
79	Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 754-761.	1.1	32
80	Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 22.	1.0	14
81	Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 385-393.	0.8	6
82	Herbal medicines: challenges in the modern world. Part 3. China and Japan. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1225-1233.	1.3	50
83	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 731-746.	2.0	20
84	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1013-1021.	1.4	53
85	Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 231-232.	0.6	14
86	Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. <i>European Journal of Pediatrics</i> , 2016, 175, 743-746.	1.3	4
87	A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F236-F243.	1.4	32
88	Challenges Associated with Route of Administration in Neonatal Drug Delivery. <i>Clinical Pharmacokinetics</i> , 2016, 55, 185-196.	1.6	25
89	Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. <i>Clinical Pharmacokinetics</i> , 2016, 55, 107-119.	1.6	42
90	Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma. <i>Frontiers in Pharmacology</i> , 2016, 7, 524.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 630-640.	1.3	26
92	A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. <i>Clinical Drug Investigation</i> , 2015, 35, 633-643.	1.1	5
93	National Trends in the Incidence, Outcomes and Charges of Pediatric Osteoarticular Infections, 1997-2012. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 672-674.	1.1	23
94	Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. <i>Journal of Burn Care and Research</i> , 2015, 36, e244-e252.	0.2	27
95	Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥ 400 Target. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 756-765.	1.0	21
96	Illustrative neonatal cases regarding drug delivery issues. <i>Journal of Paediatrics and Child Health</i> , 2015, 51, 478-481.	0.4	1
97	Clinical Pharmacokinetics of Inhaled Antimicrobials. <i>Clinical Pharmacokinetics</i> , 2015, 54, 473-492.	1.6	20
98	Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. <i>Infectious Diseases and Therapy</i> , 2015, 4, 187-198.	1.8	55
99	Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. <i>Pediatric Research</i> , 2015, 78, 315-322.	1.1	42
100	Special population considerations and regulatory affairs for clinical research. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 45-54.	2.1	35
101	Pharmacokinetic considerations in the use of antivirals in neonates. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1861-1878.	1.5	3
102	Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC-MS-MS. <i>Journal of Analytical Toxicology</i> , 2015, 39, 526-531.	1.7	2
103	Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 205-219.	1.5	32
104	Levofloxacin inhalation solution for the treatment of chronic <i>Pseudomonas aeruginosa</i> infection among patients with cystic fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 13-22.	1.0	20
105	Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. <i>Paediatric Anaesthesia</i> , 2015, 25, 222-230.	0.6	25
106	Ethics of Drug Studies in the Newborn. <i>Paediatric Drugs</i> , 2015, 17, 37-42.	1.3	13
107	Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 505-507.	1.5	12
108	Pharmacokinetic modeling of therapies for systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 587-603.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Population Pharmacokinetics of Darbeoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1237-1244.	1.6	7
110	Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 405-409.	1.1	0
111	Relationship Between Zolpidem Concentrations and Sleep Parameters in Pediatric Burn Patients. <i>Journal of Burn Care and Research</i> , 2015, 36, 137-144.	0.2	6
112	Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. <i>Paediatric Anaesthesia</i> , 2015, 25, 211-216.	0.6	8
113	An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 53-65.	1.5	3
114	Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 212-220.	1.0	18
115	Neonatal Magnesium Levels Correlate with Motor Outcomes in Premature Infants: A Long-Term Retrospective Cohort Study. <i>Frontiers in Pediatrics</i> , 2014, 2, 120.	0.9	8
116	Utilization of Optimal Study Design for Maternal and Fetal Sheep Propofol Pharmacokinetics Study: A Preliminary Study. <i>Current Clinical Pharmacology</i> , 2014, 9, 64-69.	0.2	3
117	Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 432-437.	1.0	17
118	Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1443-1446.	1.5	6
119	Preliminary Assessment of Zolpidem Pharmacokinetics in Pediatric Burn Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 295-301.	1.0	6
120	Intrapartum Magnesium Sulfate and the Potential for Cardiopulmonary Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 544-548.	1.0	6
121	Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 71-79.	0.8	23
122	Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 215-222.	1.1	6
123	Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2014, 53, 429-454.	1.6	37
124	Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. <i>Paediatric Drugs</i> , 2014, 16, 169-177.	1.3	47
125	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. <i>Pharmaceutical Research</i> , 2014, 31, 754-767.	1.7	67
126	Considerations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis. <i>Paediatric Drugs</i> , 2014, 16, 67-81.	1.3	31

#	ARTICLE	IF	CITATIONS
127	Intravenous drug delivery in neonates: lessons learnt. <i>Archives of Disease in Childhood</i> , 2014, 99, 590-594.	1.0	48
128	Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. <i>International Journal of Cardiology</i> , 2014, 172, e19-e21.	0.8	4
129	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1371-1388.	2.0	12
130	Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration. <i>Pharmaceutical Research</i> , 2014, 31, 2643-2654.	1.7	70
131	Development of levofloxacin inhalation solution to treat <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2014, 8, 13-21.	1.0	25
132	Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 336-345.	1.3	17
133	Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. <i>Indian Journal of Microbiology</i> , 2014, 54, 389-395.	1.5	3
134	Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2014, 53, 581-610.	1.6	37
135	Amikacin population pharmacokinetics among paediatric burn patients. <i>Burns</i> , 2014, 40, 311-318.	1.1	25
136	Maternal Magnesium Sulphate Exposure Predicts Neonatal Magnesium Blood Concentrations. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 318-322.	1.2	15
137	Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 161-166.	1.1	7
138	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. <i>Pediatric Pulmonology</i> , 2013, 48, 1047-1061.	1.0	51
139	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. <i>Pediatric Pulmonology</i> , 2013, 48, 1-7.	1.0	15
140	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. <i>Pediatric Pulmonology</i> , 2013, 48, 211-220.	1.0	32
141	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. <i>Pediatric Pulmonology</i> , 2013, 48, 107-122.	1.0	46
142	Metabolic and toxicological considerations for sepsis drug treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 79-89.	1.5	2
143	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. <i>Pediatric Pulmonology</i> , 2013, 48, 525-537.	1.0	27
144	Variability of Histamine Pharmacodynamic Response in Children With Allergic Rhinitis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 731-737.	1.0	7

#	ARTICLE	IF	CITATIONS
145	Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis. <i>Pharmacotherapy</i> , 2013, 33, 1288-1296.	1.2	41
146	Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. <i>Journal of Bioequivalence & Bioavailability</i> , 2013, 05, 244-247.	0.1	16
147	Population Pharmacokinetic Modeling of Risperidone and 9-Hydroxyrisperidone to Estimate CYP2D6 Subpopulations in Children and Adolescents. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 535-544.	1.0	26
148	Fundamentals of Population Pharmacokinetic Modelling. <i>Clinical Pharmacokinetics</i> , 2012, 51, 515-525.	1.6	87
149	Fundamentals of Population Pharmacokinetic Modelling. <i>Clinical Pharmacokinetics</i> , 2012, 51, 573-590.	1.6	81
150	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatric Pulmonology</i> , 2012, 47, 1147-1158.	1.0	35
151	Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance. <i>Clinical Pharmacokinetics</i> , 2012, 51, 105-117.	1.6	99
152	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 727-740.	1.1	42
153	Fundamentals of Population Pharmacokinetic Modelling. <i>Clinical Pharmacokinetics</i> , 2012, 51, 573-590.	1.6	1
154	Fundamentals of Population Pharmacokinetic Modelling. <i>Clinical Pharmacokinetics</i> , 2012, 51, 515-525.	1.6	22
155	The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease. <i>Clinical Pharmacokinetics</i> , 2011, 50, 1-24.	1.6	50
156	Cave air and hydrological controls on prior calcite precipitation and stalagmite growth rates: Implications for palaeoclimate reconstructions using speleothems. <i>Geochimica Et Cosmochimica Acta</i> , 2011, 75, 3915-3929.	1.6	61
157	Pharmacokinetics of Levetiracetam in Neonates with Seizures. <i>Journal of Pediatrics</i> , 2011, 159, 152-154.e3.	0.9	66
158	Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 307-313.	1.6	55
159	Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients. <i>Clinical Therapeutics</i> , 2011, 33, 1844-1850.	1.1	12
160	Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study. <i>Clinical Therapeutics</i> , 2011, 33, 1524-1536.	1.1	14
161	Optimal study design for pioglitazone in septic pediatric patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 433-447.	0.8	9
162	Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 465-471.	1.2	17

#	ARTICLE	IF	CITATIONS
163	Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. <i>Biopharmaceutics and Drug Disposition</i> , 2009, 30, 276-280.	1.1	8
164	Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 705-713.	0.8	47
165	Individualised dosing of amikacin in neonates. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1267-1268.	0.8	2
166	Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 465-471.	1.2	9
167	Individualising netilmicin dosing in neonates. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1201-1208.	0.8	9
168	Utility of Interleukin-12 and Interleukin-10 in Comparison with Other Cytokines and Acute-Phase Reactants in the Diagnosis of Neonatal Sepsis. <i>American Journal of Perinatology</i> , 2008, 25, 629-636.	0.6	52
169	A simple binding assay for the direct determination of biotin in urine. <i>Clinica Chimica Acta</i> , 2005, 360, 60-66.	0.5	11
170	Effectiveness of phosphodiesterase type 5 inhibitors on the treatment of thin endometrium and pregnancy outcomes: An systematic review. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 0, , 228402652210944.	0.3	0
171	Optimal Dosing of Enoxaparin in Overweight and Obese Children. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	3